Palomar (PLMR) Expected to Announce Quarterly Earnings on Monday

Key Points

• Palomar is expected to report Q1 2026 results after the market close on Monday, May 4; analysts forecast $2.17 EPS and $560.44 million in revenue, with a conference call set for May 5 at 12:00 PM ET.
• In the prior quarter (reported Feb. 11) Palomar beat expectations with $2.24 EPS and $253.36 million in revenue, a 62.7% year‑over‑year increase, and analysts now project about $9 EPS for the current fiscal year and $10 for the next.
• Analysts are largely bullish—the stock has an average rating of Buy and a consensus target of $161.75—but insiders have recently trimmed positions, selling 65,132 shares over the last three months.

Palomar (NASDAQ:PLMR - Get Free Report) is expected to be announcing its Q1 2026 results after the market closes on Monday, May 4th. Analysts expect the company to announce earnings of $2.17 per share and revenue of $560.4390 million for the quarter. Interested persons can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 12:00 PM ET.

Palomar (NASDAQ:PLMR - Get Free Report) last issued its earnings results on Wednesday, February 11th. The company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.06 by $0.18. The company had revenue of $253.36 million during the quarter, compared to the consensus estimate of $204.58 million. Palomar had a return on equity of 22.77% and a net margin of 22.50%.The firm's revenue for the quarter was up 62.7% compared to the same quarter last year. During the same period last year, the business posted $1.52 EPS. On average, analysts expect Palomar to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Palomar Price Performance

Shares of PLMR opened at $126.07 on Monday. The stock has a 50-day moving average of $124.10 and a 200-day moving average of $124.58. The company has a market cap of $3.34 billion, a PE ratio of 17.56 and a beta of 0.54. Palomar has a one year low of $107.75 and a one year high of $175.85.

Analyst Ratings Changes

Several research firms recently issued reports on PLMR. Evercore began coverage on shares of Palomar in a research report on Monday, February 9th. They issued an "outperform" rating and a $150.00 price target for the company. Zacks Research raised shares of Palomar from a "hold" rating to a "strong-buy" rating in a research report on Thursday, April 16th. Keefe, Bruyette & Woods lifted their price target on shares of Palomar from $183.00 to $186.00 and gave the company an "outperform" rating in a research report on Tuesday, April 7th. JPMorgan Chase & Co. lifted their price target on shares of Palomar from $155.00 to $160.00 and gave the company an "overweight" rating in a research report on Monday, February 23rd. Finally, Wall Street Zen downgraded Palomar from a "buy" rating to a "hold" rating in a research note on Sunday, March 1st. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $161.75.

Insider Transactions at Palomar

In related news, CEO Mac Armstrong sold 11,484 shares of the business's stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $119.88, for a total transaction of $1,376,701.92. Following the transaction, the chief executive officer directly owned 91,737 shares in the company, valued at approximately $10,997,431.56. The trade was a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Jon Christianson sold 3,000 shares of the business's stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $125.00, for a total transaction of $375,000.00. Following the transaction, the president owned 62,919 shares in the company, valued at approximately $7,864,875. This trade represents a 4.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 65,132 shares of company stock worth $7,989,780 over the last three months. 3.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Palomar

Several institutional investors have recently modified their holdings of PLMR. Royal Bank of Canada grew its holdings in shares of Palomar by 49.1% in the first quarter. Royal Bank of Canada now owns 2,956 shares of the company's stock valued at $406,000 after acquiring an additional 974 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Palomar by 5.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,427 shares of the company's stock valued at $2,115,000 after acquiring an additional 791 shares in the last quarter. NewEdge Advisors LLC bought a new position in shares of Palomar in the first quarter valued at approximately $66,000. United Services Automobile Association bought a new position in shares of Palomar in the first quarter valued at approximately $223,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Palomar by 11.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 72,661 shares of the company's stock valued at $9,960,000 after acquiring an additional 7,754 shares in the last quarter. 90.25% of the stock is owned by institutional investors.

Palomar Company Profile

Palomar Holdings, Inc NASDAQ: PLMR is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.